Revenues of pharmaceutical companies have remained unscathed during the COVID-19 pandemic although operations were disrupted during the lockdowns imposed to curb its spread.
GlobalData has conducted a survey to assess the primary concerns related to the COVID-19 outbreak for pharmaceutical companies dealing with drugs in different stages of development, including companies without marketed drugs, companies with predominantly marketed drugs, and companies with pipeline and marketed drugs.
Go deeper with GlobalData
Primary concerns for pharmaceutical businesses related to the COVID-19 outbreak by company type
Analysis of the survey results shows that employee safety was the primary concern for companies. The concern was relatively lower for companies without marketed drugs and has decreased further in Q3, to 17% from 20% in Q1.
Companies with predominantly marketed drugs had a higher concern over employee safety, at 21% in Q1. The concern increased significantly to 32% by Q3.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEmployee safety as a concern increased for companies with pipeline and marketed drugs as well, from 22% in Q1 to 24% in Q3.
Clinical trial disruption was the second biggest primary concern for companies without marketed drugs and has increased from 19% in Q1 to 22% in Q3.
Impact on supply chain was the second most primary concern for the other company types as classified by the survey. It was a concern for 21% in Q1 for companies with predominantly marketed drugs and those with pipeline and marketed drugs. The concern increased to 26% in Q3 for companies with predominantly marketed drugs but decreased for companies with pipeline and marketed drugs, to 19%.
Supply chain disruption was a relatively lesser concern for companies without marketed drugs, at 18% in Q1 and 17% in Q3.
The concerns regarding clinical trial disruption declined for companies with pipeline and marketed drugs (from 16% in Q1 to 15% in Q3) as well as for companies with predominantly marketed drugs (from 9% in Q1 to 0% in Q3).
The concerns regarding CRO disruptions increased significantly for companies with predominantly marketed drugs from 1% in Q1 to 10% in Q3 and slightly for companies without marketed drugs (from 16% in Q1 to 17% in Q3). It, however, declined for companies with pipeline and marketed drugs, from 9% in Q1 to 7% in Q3.
Business development concerns increased for companies without marketed drugs and companies with pipeline and marketed drugs, while it decreased for companies with predominantly marketed drugs.
Concerns regarding medical meeting closures declined for companies with predominantly marketed drugs and companies with pipeline and marketed drugs, while it increased for companies without marketed drugs.
Other concerns increased for companies without marketed drugs and those with pipeline and marketed drugs, while it declined for companies with predominantly marketed drugs.
The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey fielded between 07 July and 30 July 2020.
